NEXMED ANNOUNCES APPOINTMENT OF DEIRDRE Y. GILLESPIE, M.D. TO THE BOARD OF DIRECTORS

NEXMED ANNOUNCES APPOINTMENT OF DEIRDRE Y. GILLESPIE, M.D. TO THE BOARD OF DIRECTORS
San Diego--(BUSINESS WIRE)-- NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that Deirdre Y. Gillespie, M.D., President and Chief Executive Officer of publicly-held La Jolla Pharmaceutical Company, has been appointed to the Company's Board of Directors, effective immediately.

Prior to joining La Jolla Pharmaceutical Company in 2006, Dr. Gillespie served from 2001 to 2005 as President and Chief Executive Officer of Oxxon Therapeutics, Inc., a privately-held pharmaceutical company spun out of Oxford University. Before that, Dr. Gillespie was Chief Operating Officer of Vical, Inc., from 2000 to 2001, and Executive Vice President and Chief Business Officer of the company, from 1998 to 2000. During her career, Dr. Gillespie also held a number of management positions at DuPont Merck Pharmaceutical Company, including Vice President of Marketing from 1990 to 1996, and at Novartis, in clinical development, from 1986 to 1990. Dr. Gillespie received her M.B.A. from the London Business School and her M.D. and B.Sc. from London University.

Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, "We are delighted to welcome Deirdre to our Board of Directors. Her proven leadership and extensive experience in the pharmaceutical industry will be invaluable to us as we continue to aggressively pursue our business expansion strategy."

The NexMed Board of Directors is comprised of seven members. Dr. Gillespie replaces Richard J. Berman, who resigned effective immediately, having not received a majority vote at the NexMed Annual Meeting on May 24, 2010.

About NexMed, Inc.

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites : http://www.nexmed.com or http://www.bio-quant.com.

Contacts:


--------------------------------------------------------------------------------
NexMed, Inc.
Edward Cox, V.P.

Investor Relations & Corporate Development NexMed, Inc.
(858) 926-5811
[email protected]

NexMed Investor Relations
Paula Schwartz

NexMed, Inc. Rx Communications Group, LLC
(917) 322-2216
[email protected]

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.